1. Home
  2. GGG vs UTHR Comparison

GGG vs UTHR Comparison

Compare GGG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GGG
  • UTHR
  • Stock Information
  • Founded
  • GGG 1926
  • UTHR 1996
  • Country
  • GGG United States
  • UTHR United States
  • Employees
  • GGG N/A
  • UTHR N/A
  • Industry
  • GGG Fluid Controls
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • GGG Industrials
  • UTHR Health Care
  • Exchange
  • GGG Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • GGG 14.8B
  • UTHR 14.4B
  • IPO Year
  • GGG N/A
  • UTHR 1999
  • Fundamental
  • Price
  • GGG $86.81
  • UTHR $292.01
  • Analyst Decision
  • GGG Hold
  • UTHR Buy
  • Analyst Count
  • GGG 3
  • UTHR 13
  • Target Price
  • GGG $87.00
  • UTHR $383.08
  • AVG Volume (30 Days)
  • GGG 747.8K
  • UTHR 463.8K
  • Earning Date
  • GGG 07-23-2025
  • UTHR 07-30-2025
  • Dividend Yield
  • GGG 1.27%
  • UTHR N/A
  • EPS Growth
  • GGG N/A
  • UTHR 18.86
  • EPS
  • GGG 2.83
  • UTHR 25.10
  • Revenue
  • GGG $2,149,411,000.00
  • UTHR $2,994,100,000.00
  • Revenue This Year
  • GGG $7.60
  • UTHR $14.58
  • Revenue Next Year
  • GGG $4.09
  • UTHR $6.34
  • P/E Ratio
  • GGG $30.68
  • UTHR $11.62
  • Revenue Growth
  • GGG N/A
  • UTHR 19.84
  • 52 Week Low
  • GGG $72.06
  • UTHR $266.98
  • 52 Week High
  • GGG $92.86
  • UTHR $417.82
  • Technical
  • Relative Strength Index (RSI)
  • GGG 51.56
  • UTHR 46.41
  • Support Level
  • GGG $84.93
  • UTHR $291.72
  • Resistance Level
  • GGG $89.67
  • UTHR $302.52
  • Average True Range (ATR)
  • GGG 1.60
  • UTHR 6.65
  • MACD
  • GGG -0.18
  • UTHR 0.77
  • Stochastic Oscillator
  • GGG 39.56
  • UTHR 42.03

About GGG Graco Inc.

Graco manufactures equipment used for managing fluids, coatings, and adhesives, specializing in difficult-to-handle materials. Graco's business is organized into three segments: industrial, process, and contractor. The Minnesota-based firm serves a wide range of end markets, including industrial, automotive, and construction, and its broad array of products include pumps, valves, meters, sprayers, and equipment used to apply coatings, sealants, and adhesives. The firm generated roughly $2.1 billion in sales in 2024.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: